Advertisement

Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study

  • Alexander PatricianEmail author
  • Maja Versic-Bratincevic
  • Tanja Mijacika
  • Ivana Banic
  • Mario Marendic
  • Davorka Sutlović
  • Željko Dujić
  • Philip N. Ainslie
Original Research

Abstract

Introduction

Therapeutic effects of cannabidiol (CBD) in specialized populations continue to emerge. Despite supra-physiological dosing being shown to be tolerable in various pathologies, optimization of CBD absorption has obvious benefits for general health and recreational usage. Our objectives were to: (1) to investigate a joint pharmacokinetic-physiological time course of multiple recreational-equivalent (< 100 mg) dosages of oral CBD in young healthy adults and (2) evaluate a newly developed technology (TurboCBD™) for the enhanced delivery of CBD.

Methods

In a double-blinded, placebo-controlled, cross-over design, 12 participants received placebo, generic 45 or 90 mg of CBD, or TurboCBD™ delivery technology capsules on five separate occasions.

Results

Although there were no differences in the 45 mg conditions, circulating CBD levels were higher with the TurboCBD™ 90 mg group at both 90 (+ 86%) and 120 (+ 65%) min compared with the 90 mg control (p < 0.05). Total area under the curve tended to be higher with TurboCBD™ 90 mg compared with 90 mg (10,865 ± 6322 ng ml−1 vs. 7114 ± 2978 ng ml−1; p = 0.088). Only the TurboCBD™ 90 mg dose was elevated greater than placebo at 30 min (p = 0.017) and remained elevated at 4 h (p = 0.002).

Conclusion

Consistent with higher bioavailability, TurboCBD™ 90 mg at the peak CBD concentration was associated with an increase in cerebral perfusion and slight reduction in blood pressure compared with baseline and the 90 mg control. Further studies are needed to establish the mechanisms of action of this technology and to explore the therapeutic potential of acute and chronic dosing on more at-risk populations.

Funding

Lexaria Bioscience Corp.

Trial Registration

ClinicalTrials.gov identifier, NCT03295903.

Keywords

Cannabidiol Cerebrovascular conductance Gas chromatography-mass spectrometry Pharmacokinetics  

Notes

Acknowledgements

The authors would like to thank the participants of the study.

Funding

The study was sponsored by Lexaria Bioscience Corp., who also funded the Rapid Service Fees. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Philip N Ainslie acts as a Scientific Advisor for Lexaria Bioscience Corp. Alexander Patrician, Maja Versic-Bratincevic, Tanja Mijackia, Ivana Banic, Mario Marendic, Davorka Sutlović and Željko Dujić declare they have no conflict of interest.

Compliance with Ethics Guidelines

All procedures were performed in accordance with the Ethics Committee at the University of Split School of Medicine and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All participants provided written informed consent prior to completion of any data collection.

Data Availability

The datasets generated and/or analyzed during the current study are not yet publicly available, but are available upon request.

References

  1. 1.
    Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–20.CrossRefGoogle Scholar
  2. 2.
    Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013;75(2):303–12.CrossRefGoogle Scholar
  3. 3.
    Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.CrossRefGoogle Scholar
  4. 4.
    McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiat. 2018;175(3):225–31.CrossRefGoogle Scholar
  5. 5.
    Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition—a systematic review. Biol Psychiat. 2016;79(7):557–67.CrossRefGoogle Scholar
  6. 6.
    Osborne AL, Solowij N, Weston-Green K. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017;72:310–24.CrossRefGoogle Scholar
  7. 7.
    Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci. 1990;87(5):1932–6.CrossRefGoogle Scholar
  8. 8.
    Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121–30.CrossRefGoogle Scholar
  9. 9.
    Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66(1):95–105.CrossRefGoogle Scholar
  10. 10.
    Zuardi AW, Cosme R, Graeff FG, Guimarães F. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7(1_suppl):82–8.CrossRefGoogle Scholar
  11. 11.
    Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015;9(3):204–10.CrossRefGoogle Scholar
  12. 12.
    Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053–67.CrossRefGoogle Scholar
  13. 13.
    Atsmon J, Heffetz D, Deutsch L, Deutsch F, Sacks H. Single-dose pharmacokinetics of oral cannabidiol following administration of PTL101: a new formulation based on gelatin matrix pellets technology. Clin Pharmacol Drug Dev. 2018;7(7):751–8.CrossRefGoogle Scholar
  14. 14.
    Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O’Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 2019.Google Scholar
  15. 15.
    Willie CK, Colino FL, Bailey DM, Tzeng YC, Binsted G, Jones LW, et al. Utility of transcranial Doppler ultrasound for the integrative assessment of cerebrovascular function. J Neurosci Methods. 2011;196(2):221–37.CrossRefGoogle Scholar
  16. 16.
    Cole WR, Arrieux JP, Schwab K, Ivins BJ, Qashu FM, Lewis SC. Test–retest reliability of four computerized neurocognitive assessment tools in an active duty military population. Arch Clin Neuropsychol. 2013;28(7):732–42.CrossRefGoogle Scholar
  17. 17.
    Hill AJ, Blundell JE. Nutrients and behaviour: research strategies for the investigation of taste characteristics, food preferences, hunger sensations and eating patterns in man. J Psychiatr Res. 1982;17(2):203–12.CrossRefGoogle Scholar
  18. 18.
    Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;377(7):699–700.CrossRefGoogle Scholar
  19. 19.
    Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–804.CrossRefGoogle Scholar
  20. 20.
    Klawitter J, Sempio C, Morlein S, De Bloois E, Klepacki J, Henthorn T, et al. An atmospheric pressure chemical ionization MS/MS assay using online extraction for the analysis of 11 cannabinoids and metabolites in human plasma and urine. Ther Drug Monit. 2017;39(5):556–64.CrossRefGoogle Scholar
  21. 21.
    Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu A-X, et al. Repeated treatment with cannabidiol but not Δ9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology. 2007;52(4):1079–87.CrossRefGoogle Scholar
  22. 22.
    Sultan SR, Millar SA, England TJ, O’Sullivan SE. A systematic review and meta-analysis of the haemodynamic effects of cannabidiol. Front Pharmacol. 2017;8:81.CrossRefGoogle Scholar
  23. 23.
    Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417–26.CrossRefGoogle Scholar
  24. 24.
    Kiernan JA. Anatomy of the temporal lobe. Epilepsy Res Treat. 2012;2012:176157.Google Scholar
  25. 25.
    Fisher JP, Hartwich D, Seifert T, Olesen ND, McNulty CL, Nielsen HB, et al. Cerebral perfusion, oxygenation and metabolism during exercise in young and elderly individuals. J Physiol. 2013;591(7):1859–70.CrossRefGoogle Scholar
  26. 26.
    Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab. 2008;7(6):476–84.CrossRefGoogle Scholar
  27. 27.
    Stanley CP, Hind WH, Tufarelli C, O’Sullivan SE. Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc Res. 2015;107(4):568–78.CrossRefGoogle Scholar
  28. 28.
    Jadoon KA, Tan GD, O’Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI insight. 2017;2(12).Google Scholar
  29. 29.
    Moulton PL, Boyko LN, Fitzpatrick JL, Petros TV. The effect of Ginkgo biloba on memory in healthy male volunteers. Physiol Behav. 2001;73(4):659–65.CrossRefGoogle Scholar
  30. 30.
    Stavro PM, Woo M, Heim TF, Leiter LA, Vuksan V. North American ginseng exerts a neutral effect on blood pressure in individuals with hypertension. Hypertension. 2005;46(2):406–11.CrossRefGoogle Scholar
  31. 31.
    Rodriguez-Leyva D, Pierce GN. The cardiac and haemostatic effects of dietary hempseed. Nutr Metab. 2010;7(7):32.CrossRefGoogle Scholar
  32. 32.
    Galiègue SM, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54–61.CrossRefGoogle Scholar
  33. 33.
    Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5(5):529–52.CrossRefGoogle Scholar
  34. 34.
    Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771–84.CrossRefGoogle Scholar
  35. 35.
    Sacerdote P, Martucci C, Vaccani A, Bariselli F, Panerai AE, Colombo A, et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol. 2005;159(1–2):97–105.CrossRefGoogle Scholar
  36. 36.
    Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, et al. Cannabidiol in medical marijuana: research vistas and potential opportunities. Pharmacol Res. 2017;121:213–8.CrossRefGoogle Scholar
  37. 37.
    Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016;30(11):3682–9.CrossRefGoogle Scholar
  38. 38.
    Stanley CP, Hind WH, O’Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol. 2013;75(2):313–22.CrossRefGoogle Scholar
  39. 39.
    Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332–8.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Centre for Heart, Lung and Vascular HealthUniversity of British ColumbiaKelownaCanada
  2. 2.Department of Toxicology and PharmacogeneticsUniversity of Split School of MedicineSplitCroatia
  3. 3.Department of Integrative PhysiologyUniversity of Split School of MedicineSplitCroatia
  4. 4.Department of Health StudiesUniversity of SplitSplitCroatia
  5. 5.Department of Pathology, Forensic Medicine and CitologyUniversity Hospital Centre SplitSplitCroatia

Personalised recommendations